Arrowhead Pharmaceuticals announced positive results from its Phase 3 PALISADE study on plozasiran, a new drug for treating familial chylomicronemia syndrome (FCS). FCS is a rare genetic condition that causes extremely high triglyceride levels, leading to serious health issues like acute pancreatitis. Currently, there are no approved treatments for FCS in the United States or
Merck & Co.’s new vaccine, CAPVAXIVE (V116), has been approved by the FDA for preventing invasive diseases and pneumonia in adults 18 and older caused by specific strains of the bacteria Streptococcus pneumoniae. This vaccine is particularly aimed at protecting adults over 50 from around 84% of invasive pneumococcal diseases. In several studies, CAPVAXIVE showed
Today the Team at JoinAStudy.ca would like to acknowledge the dedicated work of one of our Investigators, Dr. Sabeen Anwar. Dr. Anwar and her team have played a key part in gathering new data to advance the knowledge of patient care for the condition of Psoriatic Arthritis. The APPRAISE study, a prospective observational investigation conducted
Researchers at the Max Planck Institute for Infection Biology in Berlin have made a discovery regarding the autoimmune disease lupus, shedding light on a mechanism that can trigger the disease in children. Lupus is characterized by severe inflammation throughout the body, leading to significant impacts on affected individuals’ lives. The research focuses on a specific immune
Merck & Co. has presented data from a phase 3 trial showcasing the potential of its pneumococcal vaccine candidate, V116, to rival Pfizer’s current market dominance in vaccines of this nature. In the United States, Prevnar 20 (Pfizer’s vaccine) currently commands a dominant 95% share. However, Merck contends that V116 offers broader protection, making it
Regeneron Pharmaceuticals and Sanofi have announced positive results from their phase 3 trial, titled NOTUS, evaluating Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD). The trial demonstrated that Dupixent significantly reduced COPD exacerbations by 34% (compared to placebo) in patients with moderate-to-severe COPD who also show evidence of type 2 inflammation of
JoinAStudy.ca is proud to offer heartfelt congratulations to Principal Investigator Dr. Anil Gupta for being awarded the prestigious Ontario College of Family Physicians (OCFP) “Award of Excellence“. His contributions to patient care, advocacy, and education have not only made a significant impact on the healthcare landscape in Ontario, but have also set a commendable standard
In a recent podcast, “Dispelling the Myth that RSV is Only a Disease of Childhood,” Dr. Anil Gupta and colleagues tackle a widely held misconception about Respiratory Syncytial Virus (RSV): that it’s solely a disease of childhood. While RSV is well-known for causing respiratory infections in infants and young children, it’s time to shed light on
Two new phase 2 studies suggest that the investigational drug orforglipron, developed by Eli Lilly, shows promise in the treatment of obesity and type 2 diabetes. Currently, GLP-1 agonists (a class of medications utilized in the treatment of type 2 diabetes mellitus and obesity) approved for these conditions are administered via under the skin injection,
Artificial intelligence (AI) has already made significant contributions and changes to many industries, and clinical research is no exception. AI has the potential to revolutionize the way clinical trials are conducted, making them faster, more efficient, and more cost-effective. In this article, we will explore how AI could impact the clinical trial industry in the